Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043449 | 0.89 | POLB (0.71) | POLBESR2ALDH1A1HPGDADRA1D | |
| SCHEMBL1043806 | 0.87 | POLB (0.60) | POLBESR2ALDH1A1HPGDADRA1D | |
| SCHEMBL1078455 | 0.85 | HTR6 (0.48) | POLBESR2ALDH1A1HPGDADRA1D | |
| SCHEMBL1874665 | 0.83 | POLB (0.52) | POLBESR2ALDH1A1HPGDADRA1D | |
| SCHEMBL1874772 | 0.83 | ADRA1D (0.53) | POLBESR2ALDH1A1ADRA1DADRA1A | |
| SCHEMBL1043743 | 0.82 | POLB (0.45) | POLBESR2ALDH1A1HPGDADRA1D | |
| SCHEMBL18358970 | 0.80 | POLB (0.75) | POLBESR2ALDH1A1HPGDADRA1D | |
| SCHEMBL8367125 | 0.80 | POLB (0.75) | POLBESR2ALDH1A1HPGDADRA1D | |
| SCHEMBL28708495 | 0.77 | HTT (0.39) | POLBESR2ALDH1A1HPGDADRA1A | |
| SCHEMBL1450868 | 0.77 | HTT (0.39) | POLBESR2ALDH1A1HPGDADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | claimed |
| EP-2271635-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-01-12 | — | — | EP | claimed |
| WO-2009133109-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2009-11-05 | — | — | WO | claimed |
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-2271635-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133109-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | POLB 4159/4885ESR2 3143/4885ALDH1A1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.